DT-Web

DB00976 - Telithromycin


Identification
Name Telithromycin
Accession Number DB00976 (APRD00483)
Type small molecule
Description Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 812.0037
Groups approved
Monoisotopic Weight 811.473143325
Pharmacology
Indication For the treatment of Pneumococcal infection, acute sinusitis, acute bacterial tonsillitis, acute bronchitis and bronchiolitis, lower respiratory tract infection and lobar (pneumococcal) pneumonia.
Mechanism of action Telithromycin acts by binding to domains II and V of 23S rRNA of the 50S ribosomal subunit. By binding at domain II, telithromycin retains activity against gram-positive cocci (e.g. Streptococcus pneumoniae) in the presence of resistance mediated by methylases (erm genes) that alter the binding site at domain V. Telithromycin may also inhibit the assembly of nascent ribosomal units. Compared to erythromycin A, telithromycin binds to the 23S rRNA with 10 times greater affinity in erythromycin-susceptible organisms and 25 times greater affinity in macrolide-resistant strains. This increased binding affinity may be conferred by the C11-12 carbamate side chain of telithromycin. The side chain appears to maintain binding at domain II in the presence of resistance mediated by alterations in domain V.
Absorption Absolute bioavailability is approximately 57%. Maximal concentrations are reached 0.5 - 4 hours following oral administration. Food intake does not affected absorption.
Protein binding 60 - 70% bound primarily to human serum albumin
Biotransformation Hepatic - estimated 50% metabolized by CYP3A4 and 50% metabolized independent of cytochrome P450
Route of elimination The systemically available telithromycin is eliminated by multiple pathways as follows: 7% of the dose is excreted unchanged in feces by biliary and/or intestinal secretion; 13% of the dose is excreted unchanged in urine by renal excretion; and 37% of the dose is metabolized by the liver.
Toxicity LD50>2000 mg/kg (PO in rats). Adverse effects are similar to those of clarithormycin and erithromycin and include diarrhea, nausea, vomiting, loose stools, abdominal pain, flatulence and dyspepsia. It may also cause dizziness, headache and taste disturbances.
Affected organisms
  • Enteric bacteria and other eubacteria
Interactions
Drug Interactions
Drug Mechanism of interaction
Abiraterone Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
Acenocoumarol Telithromycin may increase the anticoagulant effect of acenocoumarol.
Alfentanil Telithromycin may reduce clearance of Alfentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Alfentanil if Telithromycin is initiated, discontinued or dose changed.
Alfuzosin Telithromycin may reduce clearance of Alfuzosin. Consider alternate therapy.
Alprazolam Telithromycin may increase the effect and toxicity of the benzodiazepine, alprazolam.
ambrisentan Telithromycin may reduce clearance of Ambrisentan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ambrisentan if Telithromycin is initiated, discontinued or dose changed.
Aminoglutethimide Aminoglutethimide may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Amiodarone Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed.
Amlodipine Telithromycin may reduce clearance of Amlopidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amlopidine if Telithromycin is initiated, discontinued or dose changed.
Amprenavir Co-administration may result in altered plasma concentrations of Amprenavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Anisindione Telithromycin may increase the anticoagulant effect of anisindione.
Aprepitant Telithromycin may reduce clearance of Aprepitant. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aprepitant if Telithromycin is initiated, discontinued or dose changed.
Aripiprazole Telithromycin may reduce clearance of Aripiprazole. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aripiprazole if Telithromycin is initiated, discontinued or dose changed.
armodafinil Telithromycin may reduce clearance of Armodafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Armodafinil if Telithromycin is initiated, discontinued or dose changed.
Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Astemizole Increased risk of cardiotoxicity and arrhythmias
Atazanavir Co-administration may result in altered plasma concentrations of Atazanavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Atorvastatin The macrolide antibiotic, telithromycin, may increase the serum concentration of atorvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if telithromycin is initiated, discontinued or dose changed.
Benzphetamine Telithromycin may reduce clearance of Benzphetamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Benzphetamine if Telithromycin is initiated, discontinued or dose changed.
Bisoprolol Telithromycin may reduce clearance of Bisoprolol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bisoprolol if Telithromycin is initiated, discontinued or dose changed.
Bortezomib Telithromycin may reduce clearance of Bortezomib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bortezomib if Telithromycin is initiated, discontinued or dose changed.
Bosentan Co-administration may cause decreased Telithromycin and increased Bosentan plasma concentrations. Consider alternate therapy.
Bretylium Increased risk of cardiotoxicity and arrhythmias
Bromazepam Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if telithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required.
Bromocriptine Telithromycin may reduce clearance of Bromocriptine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bromocriptine if Telithromycin is initiated, discontinued or dose changed.
Budesonide Telithromycin may reduce clearance of Budesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Budesonide if Telithromycin is initiated, discontinued or dose changed.
Buprenorphine Telithromycin may reduce clearance of Buprenorphine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buprenorphine if Telithromycin is initiated, discontinued or dose changed.
Buspirone Telithromycin may reduce clearance of Buspirone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buspirone if Telithromycin is initiated, discontinued or dose changed.
Busulfan Telithromycin may reduce clearance of Busulfan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Busulfan if Telithromycin is initiated, discontinued or dose changed.
Cabazitaxel Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
Calcitriol Telithromycin may reduce clearance of Calcitriol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Calcitriol if Telithromycin is initiated, discontinued or dose changed.
Carbamazepine Co-administration may cause decreased Telithromycin and increased Carbemazepine plasma concentrations. Consider alternate therapy.
Chlordiazepoxide Telithromycin may reduce clearance of Chlordiazepoxide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlordiazepoxide if Telithromycin is initiated, discontinued or dose changed.
Chloroquine Telithromycin may reduce clearance of Chloroquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chloroquine if Telithromycin is initiated, discontinued or dose changed.
Chlorpheniramine Telithromycin may reduce clearance of Chlorpheniramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlorpheniramine if Telithromycin is initiated, discontinued or dose changed.
Ciclesonide Telithromycin may reduce clearance of Ciclesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ciclesonide if Telithromycin is initiated, discontinued or dose changed.
Cilostazol Telithromycin may reduce clearance of Cilostazol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cilostazol if Telithromycin is initiated, discontinued or dose changed.
Cinacalcet Telithromycin may reduce clearance of Cinacalcet. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cinacalcet if Telithromycin is initiated, discontinued or dose changed.
Cisapride Telithromycin may reduce clearance of Cisapride. Concomitant therapy is contraindicated.
Citalopram Telithromycin may reduce clearance of Citalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Citalopram if Telithromycin is initiated, discontinued or dose changed.
Clarithromycin Co-administration may result in altered plasma concentrations of Clarithromycin and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Clobazam Telithromycin may reduce clearance of Clobazam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clobazam if Telithromycin is initiated, discontinued or dose changed.
Clonazepam Telithromycin may reduce clearance of Clonazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clonazepam if Telithromycin is initiated, discontinued or dose changed.
Clorazepate Telithromycin may reduce clearance of Clorazepate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clorazepate if Telithromycin is initiated, discontinued or dose changed.
Cocaine Telithromycin may reduce clearance of Cocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cocaine if Telithromycin is initiated, discontinued or dose changed.
Colchicine Telithromycin may reduce clearance of Colchicine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Colchicine if Telithromycin is initiated, discontinued or dose changed.
Conivaptan Co-administration may result in altered plasma concentrations of Conivaptan and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Cyclosporine Telithromycin may reduce clearance of cyclosporine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of cyclosporine if telithromycin is initiated, discontinued or dose changed.
Dantrolene Telithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if telithromycin is initiated, discontinued or dose changed.
Dapsone Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed.
Darifenacin Telithromycin may reduce clearance of Darifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Darifenacin if Telithromycin is initiated, discontinued or dose changed.
Darunavir Co-administration may result in altered plasma concentrations of Darunavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Dasatinib Telithromycin may reduce clearance of Dasatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dasatinib if Telithromycin is initiated, discontinued or dose changed.
Delavirdine Delavirdine may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Dexamethasone Co-administration may cause decreased Telithromycin and increased Dexamethasone plasma concentrations. Consider alternate therapy.
Diazepam Telithromycin may reduce clearance of Diazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diazepam if Telithromycin is initiated, discontinued or dose changed.
Dicumarol Telithromycin may increase the anticoagulant effect of dicumarol.
Digitoxin Telithromycin may reduce clearance of Digitoxin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Digitoxin if Telithromycin is initiated, discontinued or dose changed.
Digoxin Telithromycin may increase the plasma concentration of Digoxin. Monitor for changes in Digoxin efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
Dihydroergotamine Telithromycin may reduce clearance of Dihydroergotamine. Concomitant therapy is contraindicated.
Diltiazem Telithromycin may reduce clearance of Diltiazem. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diltiazem if Telithromycin is initiated, discontinued or dose changed.
Disopyramide Telithromycin may reduce clearance of Disopyramide. Concomitant therapy should be avoided.
Docetaxel Telithromycin may reduce clearance of Docetaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Docetaxel if Telithromycin is initiated, discontinued or dose changed.
Dofetilide Increased risk of cardiotoxicity and arrhythmias
Doxepin Telithromycin may reduce clearance of Doxepin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxepin if Telithromycin is initiated, discontinued or dose changed.
Doxorubicin Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed.
doxorubicin TransDrug Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed.
Dronedarone Telithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
Efavirenz Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Eletriptan Telithromycin may reduce clearance of Eletriptan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eletriptan if Telithromycin is initiated, discontinued or dose changed.
Eplerenone Telithromycin may reduce clearance of Eplerenone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eplerenone if Telithromycin is initiated, discontinued or dose changed.
Ergoloid mesylate Telithromycin may reduce clearance of Ergoloid mesylates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergoloid mesylates if Telithromycin is initiated, discontinued or dose changed.
Ergonovine Telithromycin may reduce clearance of Ergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergonivine if Telithromycin is initiated, discontinued or dose changed.
Ergotamine Telithromycin may reduce clearance of Ergotamine. Concomitant therapy is contraindicated.
Erlotinib Telithromycin may reduce clearance of Erlotinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erlotinib if Telithromycin is initiated, discontinued or dose changed.
Erythromycin Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed.
Escitalopram Telithromycin may reduce clearance of Escitalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Escitalopram if Telithromycin is initiated, discontinued or dose changed.
Eszopiclone Telithromycin may reduce clearance of Eszopiclone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eszopiclone if Telithromycin is initiated, discontinued or dose changed.
Ethosuximide Telithromycin may reduce clearance of Ethosuximide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ethosuximide if Telithromycin is initiated, discontinued or dose changed.
Etoposide Telithromycin may reduce clearance of Etoposide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Etoposide if Telithromycin is initiated, discontinued or dose changed.
Felbamate Telithromycin may reduce clearance of Felbamate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felbamate if Telithromycin is initiated, discontinued or dose changed.
Felodipine Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed.
Fentanyl Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed.
Flunisolide Telithromycin may reduce clearance of Flunisolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flunisolide if Telithromycin is initiated, discontinued or dose changed.
Flurazepam Telithromycin may reduce clearance of Flurazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flurazepam if Telithromycin is initiated, discontinued or dose changed.
Flutamide Telithromycin may reduce clearance of Flutamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flutamide if Telithromycin is initiated, discontinued or dose changed.
Fluticasone Propionate Telithromycin may reduce clearance of Fluticasone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fluticasone if Telithromycin is initiated, discontinued or dose changed.
Fosamprenavir Fosamprevavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Fosphenytoin Fosphenytoin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Gefitinib Telithromycin may reduce clearance of Gefitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Gefitinib if Telithromycin is initiated, discontinued or dose changed.
Halofantrine Telithromycin may reduce clearance of Halofantrine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Halofantrine if Telithromycin is initiated, discontinued or dose changed.
Haloperidol Telithromycin may reduce clearance of Haloperidol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Haloperidol if Telithromycin is initiated, discontinued or dose changed.
Ifosfamide Telithromycin may reduce clearance of Ifosfamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ifosfamide if Telithromycin is initiated, discontinued or dose changed.
Imatinib Co-administration may result in altered plasma concentrations of Imatinib and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Indinavir Indinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Irinotecan Telithromycin may reduce clearance of Irinotecan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Irinotecan if Telithromycin is initiated, discontinued or dose changed.
Isoniazid Isoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Isosorbide Dinitrate Telithromycin may reduce clearance of Isosorbide Dinitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Dinitrate if Telithromycin is initiated, discontinued or dose changed.
Isosorbide Mononitrate Telithromycin may reduce clearance of Isosorbide Mononitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Mononitrate if Telithromycin is initiated, discontinued or dose changed.
Isradipine Telithromycin may reduce clearance of Isradipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isradipine if Telithromycin is initiated, discontinued or dose changed.
Itraconazole Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Ivacaftor Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
Ixabepilone Telithromycin may reduce clearance of Ixabepilone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ixabepilone if Telithromycin is initiated, discontinued or dose changed.
Ketamine Telithromycin may reduce clearance of Ketamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ketamine if Telithromycin is initiated, discontinued or dose changed.
Ketoconazole Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Lapatinib Telithromycin may reduce clearance of Lapatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lapatinib if Telithromycin is initiated, discontinued or dose changed.
Lidocaine Telithromycin may reduce clearance of Lidocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lidocaine if Telithromycin is initiated, discontinued or dose changed.
Lopinavir Lopinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Lovastatin Telithromycin may increase the adverse effects of lovastatin by decreasing its metabolism. Concomitant therapy should be avoided.
Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Maraviroc Telithromycin may reduce clearance of Maraviroc. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Maraviroc if Telithromycin is initiated, discontinued or dose changed.
Mefloquine Telithromycin may reduce clearance of Mefloquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mefloquine if Telithromycin is initiated, discontinued or dose changed.
Methadone Telithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed.
Methylergonovine Telithromycin may reduce clearance of Methylergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methylergonovine if Telithromycin is initiated, discontinued or dose changed.
Methysergide Risk of ergotism and severe ischemia with this association
Metoprolol Telithromycin may possibly increase metoprolol effect
Miconazole Miconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Midazolam Telithromycin may increase the effect and toxicity of the benzodiazepine, midazolam.
Mirtazapine Telithromycin may reduce clearance of Mirtazapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mirtazapine if Telithromycin is initiated, discontinued or dose changed.
Modafinil Telithromycin may reduce clearance of Modafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Modafinil if Telithromycin is initiated, discontinued or dose changed.
Moricizine Telithromycin may reduce clearance of Moricizine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Moricizine if Telithromycin is initiated, discontinued or dose changed.
Nafcillin Nafcillin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Nateglinide Telithromycin may reduce clearance of Nateglenide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nateglenide if Telithromycin is initiated, discontinued or dose changed.
Nefazodone Co-administration may result in altered plasma concentrations of Nefazodone and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Nelfinavir Nelfinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Nevirapine Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Nicardipine Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Nifedipine Telithromycin may reduce clearance of Nifedipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nifedipine if Telithromycin is initiated, discontinued or dose changed.
Nilotinib Telithromycin may reduce clearance of Nilotinib. Concomitant therapy should be avoided.
Nimodipine Telithromycin may reduce clearance of Nimodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nimodipine if Telithromycin is initiated, discontinued or dose changed.
Nisoldipine Telithromycin may reduce clearance of Nisoldipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nisoldipine if Telithromycin is initiated, discontinued or dose changed.
Nitrendipine Telithromycin may reduce clearance of Nitrendipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nitrendipine if Telithromycin is initiated, discontinued or dose changed.
Oxcarbazepine Oxcarbazepine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Paclitaxel Telithromycin may reduce clearance of Paclitaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Paclitaxel if Telithromycin is initiated, discontinued or dose changed.
Pentobarbital Pentobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Pergolide Telithromycin may reduce clearance of Pergolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pergolide if Telithromycin is initiated, discontinued or dose changed.
Phencyclidine Telithromycin may reduce clearance of Phencyclidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Phencyclidine if Telithromycin is initiated, discontinued or dose changed.
Phenobarbital Phenobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Phenytoin Phenytoin may decrease the plasma concentration of Telithromycin by increasing its metabolism. Consider alternate therapy.
Pimozide Telithromycin may reduce clearance of Pimozide. Concomitant therapy is contraindicated.
Pipotiazine Telithromycin may reduce clearance of Pipotiazine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pipotiazine if Telithromycin is initiated, discontinued or dose changed.
Ponatinib Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
Posaconazole Posaconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Praziquantel Telithromycin may reduce clearance of Praziquantel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Praziquantel if Telithromycin is initiated, discontinued or dose changed.
Primidone Primidone may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Quetiapine Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed.
Quinidine Co-administration may result in altered plasma concentrations of Quinidine and/or Telithromycin. Consider alternate therapy or monitor for changes in the the therapeutic/adverse effects of both agents during concomitant therapy.
Quinidine barbiturate Increased risk of cardiotoxicity and arrhythmias
Quinine Telithromycin may reduce clearance of Quinine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quinine if Telithromycin is initiated, discontinued or dose changed.
Ranolazine Telithromycin may reduce clearance of Ranolazine. Concomitant therapy should be avoided.
Regorafenib Strong CYP3A4 inhibitors may increase levels of regorafenib.
Repaglinide Telithromycin may reduce clearance of Repaglinide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Repaglinide if Telithromycin is initiated, discontinued or dose changed.
Rifabutin Rifabutin may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Rifampin Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided.
Rifapentine Rifapentine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
Ritonavir Ritonavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Rivaroxaban Telithromycin may reduce clearance of Rivaroxaban. Concomitant therapy is contraindicated.
Salmeterol Telithromycin may reduce clearance of Salmeterol. Concomitant therapy is contraindicated.
Saquinavir Saquinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Sibutramine Telithromycin may reduce clearance of Sibutramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sibutramine if Telithromycin is initiated, discontinued or dose changed.
Sildenafil Telithromycin may reduce clearance of Sildenafil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sildenafil if Telithromycin is initiated, discontinued or dose changed.
Simvastatin Telithromycin may increase the adverse effects of simvastatin by decreasing its metabolism. Concomitant therapy should be avoided.
Sirolimus Telithromycin may reduce clearance of Sirolimus. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sirolimus if Telithromycin is initiated, discontinued or dose changed.
Solifenacin Telithromycin may reduce clearance of Solifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Solifenacin if Telithromycin is initiated, discontinued or dose changed.
Sotalol Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Spiramycin Telithromycin may reduce clearance of Spiramycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Spiramycin if Telithromycin is initiated, discontinued or dose changed.
Sufentanil Telithromycin may reduce clearance of Sufentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sufentanil if Telithromycin is initiated, discontinued or dose changed.
Sunitinib Telithromycin may reduce clearance of Sunitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sunitinib if Telithromycin is initiated, discontinued or dose changed.
Tacrolimus Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Telithromycin, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance.
Tadalafil Telithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
Tamoxifen Telithromycin may reduce clearance of Tamoxifen. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tamoxifen if Telithromycin is initiated, discontinued or dose changed.
Tamsulosin Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Telithromycin is initiated, discontinued, or dose changed.
Temsirolimus Telithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
Teniposide The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Telithromycin is initiated, discontinued or dose changed.
Terfenadine Increased risk of cardiotoxicity and arrhythmias
Tetrabenazine Telithromycin may increase the QTc-prolonging effect of Tetrabenazine. Concomitant therapy should be avoided.
Theophylline Telithromycin may reduce clearance of Theophylline. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Theophylline if Telithromycin is initiated, discontinued or dose changed.
Thioridazine Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided.
Thiothixene May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Tiagabine The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Telithromycin is initiated, discontinued or dose changed.
Tolterodine Telithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Tramadol Telithromycin may decrease the metabolism and clearance of tramadol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of tramadol if telithromycin is initiated, discontinued or dose changed.
Trazodone The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
Triazolam Telithromycin may increase the effect and toxicity of the benzodiazepine, triazolam.
Trimipramine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Telithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution.
Valproic Acid The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Telithromycin is initiated, discontinued or dose changed.
Vardenafil Telithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
Vemurafenib Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
Venlafaxine Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Telithromycin is initiated, discontinued, or dose changed.
Verapamil Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed.
Vinblastine Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed.
Vincristine Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Telithromycin is initiated, discontinued or dose changed.
Vinorelbine Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Telithromycin is initiated, discontinued or dose changed.
Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of telithromycin by decreasing its metabolism. Telithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. QTc interval prolongation may also occur.
Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Warfarin Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy.
Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
Zolpidem Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if telithromycin is initiated, discontinued or dose changed.
Zonisamide Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if telithromycin is initiated, discontinued or dose changed.
Zopiclone Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if telithromycin is initiated, discontinued or dose changed.
Zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Food Interactions
  • Take without regard to meals.

Targets


23S rRNA
Name 23S rRNA
Gene Name Not Available
Pharmacological action yes
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Reinert RR, Al-Lahham A: Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22. Antimicrob Agents Chemother. 2005 Jul;49(7):3011-3. - Pubmed
  • Farrell DJ, Shackcloth J, Barbadora KA, Green MD: Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations. Antimicrob Agents Chemother. 2006 Feb;50(2):817-8. - Pubmed
  • Hirakata Y, Mizuta Y, Wada A, Kondoh A, Kurihara S, Izumikawa K, Seki M, Yanagihara K, Miyazaki Y, Tomono K, Kohno S: The first telithromycin-resistant Streptococcus pneumoniae isolate in Japan associated with erm(B) and mutations in 23S rRNA and riboprotein L4. Jpn J Infect Dis. 2007 Feb;60(1):48-50. - Pubmed
  • Champney WS, Mentens N, Zurawick K: An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47. - Pubmed
DTHybrid score Not Available

Enzymes


Cytochrome P450 3A7
Name Cytochrome P450 3A7
Gene Name CYP3A7
Actions substrate,inhibitor
References
DTHybrid score 0.2836
Cytochrome P450 1A2
Name Cytochrome P450 1A2
Gene Name CYP1A2
Actions substrate
References
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.3476
Cytochrome P450 3A4
Name Cytochrome P450 3A4
Gene Name CYP3A4
Actions substrate,inhibitor
References
  • Flockhart DA. - Drug Interactions: Cytochrome P450 Drug Interaction Table
  • Bearden DT, Neuhauser MM, Garey KW: Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy. 2001 Oct;21(10):1204-22. - Pubmed
  • Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ: The ketolides: a critical review. Drugs. 2002;62(12):1771-804. - Pubmed
  • Reed M, Wall GC, Shah NP, Heun JM, Hicklin GA: Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60. Epub 2004 Dec 14. - Pubmed
  • Shi J, Chapel S, Montay G, Hardy P, Barrett JS, Sica D, Swan SK, Noveck R, Leroy B, Bhargava VO: Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther. 2005 Mar;43(3):123-33. - Pubmed
  • Nguyen M, Chung EP: Telithromycin: the first ketolide antimicrobial. Clin Ther. 2005 Aug;27(8):1144-63. - Pubmed
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.5623
Cytochrome P450 3A5
Name Cytochrome P450 3A5
Gene Name CYP3A5
Actions substrate,inhibitor
References
DTHybrid score 0.3526
Cytochrome P450 2D6
Name Cytochrome P450 2D6
Gene Name CYP2D6
Actions inhibitor
References
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.4058

Predictions


Id Partner name Gene Name Score
1588 Multidrug resistance protein 1 ABCB1 0.2075
4757 Cytochrome P450 2C9 CYP2C9 0.2073
6016 Cytochrome P450 2C19 CYP2C19 0.199
4924 Cytochrome P450 2C8 CYP2C8 0.1543
6030 Cytochrome P450 2B6 CYP2B6 0.1218
6013 Cytochrome P450 2E1 CYP2E1 0.1052
6024 Cytochrome P450 1A1 CYP1A1 0.1016
5718 Cytochrome P450 2A6 CYP2A6 0.0667
492 Histamine H1 receptor HRH1 0.062
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0597
587 Serum albumin ALB 0.0563
824 Sodium-dependent serotonin transporter SLC6A4 0.0515
831 D(2) dopamine receptor DRD2 0.0478
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0469
502 5-hydroxytryptamine 2A receptor HTR2A 0.0467
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0446
556 Alpha-1A adrenergic receptor ADRA1A 0.0431
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0427
847 Mu-type opioid receptor OPRM1 0.0426
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0425
20 Prostaglandin G/H synthase 1 PTGS1 0.0422
6145 Solute carrier family 22 member 1 SLC22A1 0.0417
862 Multidrug resistance-associated protein 1 ABCC1 0.0409
320 5-hydroxytryptamine 1A receptor HTR1A 0.0397
6106 Cytochrome P450 2C18 CYP2C18 0.0388
318 Alpha-2A adrenergic receptor ADRA2A 0.0368
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0357
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0354
3811 Cytochrome P450 19A1 CYP19A1 0.0333
1898 Cytochrome P450 1B1 CYP1B1 0.0331
766 Beta-2 adrenergic receptor ADRB2 0.0327
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0321
6031 Cytochrome P450 3A43 CYP3A43 0.0317
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0316
6144 Solute carrier family 22 member 2 SLC22A2 0.0316
590 5-hydroxytryptamine 2C receptor HTR2C 0.0308
23 D(1A) dopamine receptor DRD1 0.0306
871 Glucocorticoid receptor NR3C1 0.0306
713 Sodium-dependent dopamine transporter SLC6A3 0.0299
467 Delta-type opioid receptor OPRD1 0.0296
193 Beta-1 adrenergic receptor ADRB1 0.0293
1729 Solute carrier family 22 member 6 SLC22A6 0.0285
638 D(3) dopamine receptor DRD3 0.0277
632 Alpha-1B adrenergic receptor ADRA1B 0.0276
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0276
118 Organic cation/carnitine transporter 2 SLC22A5 0.0275
341 5-hydroxytryptamine 3 receptor HTR3A 0.0269
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0268
696 Kappa-type opioid receptor OPRK1 0.0266
776 Bile salt export pump ABCB11 0.0265
36 Insulin receptor INSR 0.0258
885 5-hydroxytryptamine 1B receptor HTR1B 0.0244
872 Gamma-aminobutyric-acid receptor subunit alpha-1 GABRA1 0.0242
731 HIV-1 protease HIV-1 protease 0.0241
817 DNA topoisomerase 2-alpha TOP2A 0.024
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0232
4115 Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D 0.0225
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0221
478 Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C 0.0219
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0217
4111 Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 0.0215
3941 Amine oxidase [flavin-containing] A MAOA 0.0213
629 Alpha-2B adrenergic receptor ADRA2B 0.0211
378 Alpha-2C adrenergic receptor ADRA2C 0.0203
477 DNA topoisomerase 4 subunit A parC 0.0201
886 DNA topoisomerase 4 subunit A parC 0.0201
6226 DNA topoisomerase 4 subunit A parC 0.0201
290 Prostaglandin G/H synthase 2 PTGS2 0.0201
6143 Solute carrier family 22 member 7 SLC22A7 0.0199
4110 Voltage-dependent L-type calcium channel subunit beta-2 CACNB2 0.0199
725 5-hydroxytryptamine 1D receptor HTR1D 0.0199
404 DNA gyrase subunit A gyrA 0.0198
6224 DNA gyrase subunit A gyrA 0.0198
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0193
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0185
432 D(4) dopamine receptor DRD4 0.0185
136 Estrogen receptor ESR1 0.0183
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0183
260 Cytochrome P450 51 ERG11 0.0182
761 Cytochrome P450 51 ERG11 0.0182
3163 Cytochrome P450 51 cyp51 0.0182
450 Muscarinic acetylcholine receptor M4 CHRM4 0.0181
6182 Cytochrome P450 2J2 CYP2J2 0.0179
833 Organic cation/carnitine transporter 1 SLC22A4 0.0176
465 Calmodulin CALM1 0.0175
6147 Solute carrier family 22 member 3 SLC22A3 0.0175
614 Progesterone receptor PGR 0.0175
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0169
204 cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A 0.0167
789 Alpha-1D adrenergic receptor ADRA1D 0.0164
198 Sodium channel protein type 10 subunit alpha SCN10A 0.0164
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0162
750 Voltage-dependent calcium channel gamma-1 subunit CACNG1 0.016
6148 Multidrug resistance-associated protein 7 ABCC10 0.016
4148 Serine/threonine-protein kinase mTOR MTOR 0.0159
485 cGMP-inhibited 3',5'-cyclic phosphodiesterase A PDE3A 0.0159
232 Corticosteroid-binding globulin SERPINA6 0.0156
2164 Multidrug resistance-associated protein 4 ABCC4 0.0153
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.0153
737 Mineralocorticoid receptor NR3C2 0.0151
762 Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 0.015
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.0148
6142 Solute carrier family 22 member 8 SLC22A8 0.0148
580 Gamma-aminobutyric-acid receptor subunit alpha-3 GABRA3 0.0148
3923 Cholinesterase BCHE 0.0147
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0147
423 Gamma-aminobutyric-acid receptor subunit alpha-2 GABRA2 0.0147
3939 Amine oxidase [flavin-containing] B MAOB 0.0146
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0146
468 Cytochrome P450 4A11 CYP4A11 0.0143
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.0138
535 Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G 0.0127
6220 Aryl hydrocarbon receptor AHR 0.0126
596 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 0.0126
818 50S ribosomal protein L10 rplJ 0.0126
631 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 0.0126
3387 3-hydroxy-3-methylglutaryl-coenzyme A reductase mvaA 0.0126
4099 Gamma-aminobutyric-acid receptor subunit beta-3 GABRB3 0.0123
163 D(1B) dopamine receptor DRD5 0.012
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0118
716 5-hydroxytryptamine 7 receptor HTR7 0.0118
504 Mast/stem cell growth factor receptor KIT 0.0117
523 Gamma-aminobutyric-acid receptor subunit alpha-5 GABRA5 0.0117
642 3-oxo-5-alpha-steroid 4-dehydrogenase 2 SRD5A2 0.0115
94 5-hydroxytryptamine 4 receptor HTR4 0.0115
811 Translocator protein TSPO 0.0114
756 Sex hormone-binding globulin SHBG 0.0113
844 Epidermal growth factor receptor EGFR 0.0109
436 5-hydroxytryptamine 2B receptor HTR2B 0.0109
16 Adenosine A1 receptor ADORA1 0.0105
1256 5-hydroxytryptamine 6 receptor HTR6 0.0104
777 Tumor necrosis factor TNF 0.0104
474 Acetylcholinesterase ACHE 0.0102
380 Cytochrome P450 17A1 CYP17A1 0.0101
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.0101
228 Beta platelet-derived growth factor receptor PDGFRB 0.0101
26 Vascular endothelial growth factor receptor 3 FLT4 0.01
1178 Adenosine A2a receptor ADORA2A 0.01
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.01
385 Potassium-transporting ATPase alpha chain 1 ATP4A 0.01
958 Insulin-like growth factor 1 receptor IGF1R 0.0097
407 Vascular endothelial growth factor receptor 2 KDR 0.0096
530 Gamma-aminobutyric-acid receptor subunit alpha-4 GABRA4 0.0096
32 Vascular endothelial growth factor receptor 1 FLT1 0.0096
841 Gamma-aminobutyric-acid receptor subunit alpha-6 GABRA6 0.0095
6020 Aldehyde oxidase AOX1 0.0095
4113 Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F 0.0093
567 Receptor tyrosine-protein kinase erbB-2 ERBB2 0.0093
4100 Gamma-aminobutyric-acid receptor subunit beta-2 GABRB2 0.009
1656 CYP2B protein CYP2B 0.0089
1010 Cytochrome P450 51A1 CYP51A1 0.0088
124 Histamine H2 receptor HRH2 0.0088
6087 Gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 0.0088
6093 Gamma-aminobutyric acid receptor subunit delta GABRD 0.0088
6089 Gamma-aminobutyric acid receptor subunit epsilon GABRE 0.0088
4604 Liver carboxylesterase 1 CES1 0.0088
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0087
29 Tubulin beta-1 chain TUBB1 0.0086
4098 Gamma-aminobutyric-acid receptor subunit beta-1 GABRB1 0.0085
6086 Gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 0.0085
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.0084
6090 Gamma-aminobutyric acid receptor subunit pi GABRP 0.0084
6088 Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 0.0084
6115 Gamma-aminobutyric acid receptor subunit rho-3 GABRR3 0.0084
6092 Gamma-aminobutyric acid receptor subunit rho-2 GABRR2 0.0084
952 Dipeptidyl peptidase 4 DPP4 0.0084
146 Androgen receptor AR 0.0084
142 Gamma-aminobutyric-acid receptor subunit rho-1 GABRR1 0.0083
768 FK506-binding protein 1A FKBP1A 0.0083
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0082
6038 Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6H 0.0082
147 Aldehyde dehydrogenase, mitochondrial ALDH2 0.0081
6091 Gamma-aminobutyric acid receptor subunit theta GABRQ 0.008
565 Extracellular calcium-sensing receptor CASR 0.008
3947 Xanthine dehydrogenase/oxidase XDH 0.008
161 Tubulin beta chain TUBB 0.008
312 Tubulin beta chain TUB2 0.008
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.008
950 Alpha platelet-derived growth factor receptor PDGFRA 0.008
427 Substance-P receptor TACR1 0.0079
705 Glutamate receptor 1 GRIA1 0.0079
173 Toll-like receptor 7 TLR7 0.0079
4237 50S ribosomal protein L22 rplV 0.0079
238 Peroxisome proliferator-activated receptor gamma PPARG 0.0079
15 Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I 0.0078
6014 Cytochrome P450 2A13 CYP2A13 0.0078
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0077
723 Cytosolic phospholipase A2 PLA2G4A 0.0077
273 Apoptosis regulator Bcl-2 BCL2 0.0077
6037 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6G 0.0076
131 Synaptic vesicular amine transporter SLC18A2 0.0076
122 P2Y purinoceptor 12 P2RY12 0.0074
208 DNA-directed RNA polymerase beta' chain rpoC 0.0074
5774 DNA-directed RNA polymerase beta' chain rpoC 0.0074
4122 Histone deacetylase 2 HDAC2 0.0072
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.0071
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.0069
2112 Toll-like receptor 9 TLR9 0.0069
4120 NADPH--cytochrome P450 reductase POR 0.0069
814 Ryanodine receptor 1 RYR1 0.0068
6154 Multidrug and toxin extrusion protein 1 SLC47A1 0.0068
6136 Multidrug resistance-associated protein 5 ABCC5 0.0067
6137 Multidrug resistance-associated protein 6 ABCC6 0.0067
1517 Beta-3 adrenergic receptor ADRB3 0.0067
528 5-hydroxytryptamine 1E receptor HTR1E 0.0067
4112 Voltage-dependent L-type calcium channel subunit beta-4 CACNB4 0.0066
4114 Voltage-dependent L-type calcium channel subunit beta-3 CACNB3 0.0066
6177 UDP-glucuronosyltransferase 1-10 UGT1A10 0.0065
4238 50S ribosomal protein L4 rplD 0.0065
5578 50S ribosomal protein L4 rplD 0.0065
6173 50S ribosomal protein L4 rplD 0.0065
6219 50S ribosomal protein L4 rplD 0.0065
165 FL cytokine receptor FLT3 0.0065
6180 UDP-glucuronosyltransferase 2B4 UGT2B4 0.0064
571 Melatonin receptor type 1A MTNR1A 0.0064
362 Melatonin receptor type 1B MTNR1B 0.0064
6102 Arylamine N-acetyltransferase 2 NAT2 0.0063
6068 Guanylate cyclase soluble subunit alpha-2 GUCY1A2 0.0063
6105 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 0.0062
1757 Myeloperoxidase MPO 0.0062
869 Estrogen receptor beta ESR2 0.0062
1024 Solute carrier family 22 member 11 SLC22A11 0.0062
17 Proto-oncogene tyrosine-protein kinase ABL1 ABL1 0.0061
1050 Bile salt sulfotransferase SULT2A1 0.006
541 cAMP-specific 3',5'-cyclic phosphodiesterase 4B PDE4B 0.006
284 DNA-directed RNA polymerase beta chain rpoB 0.006
5773 DNA-directed RNA polymerase beta chain rpoB 0.006
333 Voltage-dependent L-type calcium channel subunit beta-1 CACNB1 0.006
6169 ATP-binding cassette sub-family A member 5 ABCA5 0.0059
2539 Tubulin alpha-1 chain TUBA4A 0.0059
2222 Equilibrative nucleoside transporter 1 SLC29A1 0.0059
6141 Sodium/bile acid cotransporter SLC10A1 0.0058
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.0057
698 B-Raf proto-oncogene serine/threonine-protein kinase BRAF 0.0056
6044 Serum paraoxonase/lactonase 3 PON3 0.0056
5251 Carbonyl reductase [NADPH] 1 CBR1 0.0056
6506 Stathmin-4 STMN4 0.0055
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0054
1852 Microtubule-associated protein 2 MAP2 0.0054
5998 Toll-like receptor 8 TLR8 0.0053
70 Type-1 angiotensin II receptor AGTR1 0.0053
712 Tubulin alpha chain TUB1 0.0052
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.0052
259 Microsomal triglyceride transfer protein large subunit MTTP 0.0052
464 Glutamate [NMDA] receptor subunit epsilon-2 GRIN2B 0.0051
469 Annexin A1 ANXA1 0.0051
4177 Proto-oncogene tyrosine-protein kinase receptor ret RET 0.0051
620 Bifunctional dihydrofolate reductase-thymidylate synthase Not Available 0.0051
295 Carbonic anhydrase 1 CA1 0.0051
6158 Solute carrier organic anion transporter family member 1C1 SLCO1C1 0.005
4199 Sphingosine 1-phosphate receptor Edg-8 S1PR5 0.005
613 Atrial natriuretic peptide receptor A NPR1 0.005
239 Coagulation factor X F10 0.005
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.005
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0049
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.0049
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.0049
951 Macrophage colony-stimulating factor 1 receptor CSF1R 0.0049
373 Transthyretin TTR 0.0049
787 Vitamin K epoxide reductase complex subunit 1 VKORC1 0.0049
1483 Membrane copper amine oxidase AOC3 0.0048
5923 Microtubule-associated protein tau MAPT 0.0048
5924 Microtubule-associated protein 4 MAP4 0.0048
6045 Voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 0.0047
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0047
738 Monocarboxylate transporter 1 SLC16A1 0.0047
511 5-hydroxytryptamine 1F receptor HTR1F 0.0046
4228 Keratin, type II cytoskeletal 7 KRT7 0.0046
3086 Plasmepsin-2 Not Available 0.0046
606 Cytochrome P450 27, mitochondrial CYP27A1 0.0046
4311 tRNA TRDMT1 0.0045
4325 tRNA trmD 0.0045
4328 tRNA trmD 0.0045
4203 Histamine N-methyltransferase HNMT 0.0045
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0045
6206 DNA-directed RNA polymerase subunit beta' rpoC 0.0045
174 Sigma 1-type opioid receptor SIGMAR1 0.0045
80 Peroxisome proliferator-activated receptor alpha PPARA 0.0043
230 ATP-binding cassette transporter sub-family C member 8 ABCC8 0.0043
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.0042
1629 Transcription factor AP-1 JUN 0.0042
4773 Deoxycytidine kinase DCK 0.0042
714 Glutathione reductase, mitochondrial GSR 0.0042
976 Platelet glycoprotein IX GP9 0.0042
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0042
275 Arachidonate 5-lipoxygenase ALOX5 0.0042
1196 Complement decay-accelerating factor CD55 0.0042
1971 cAMP-specific 3',5'-cyclic phosphodiesterase 4A PDE4A 0.0042
3932 Glutathione S-transferase A2 GSTA2 0.0041
3804 Sodium channel protein type 4 subunit alpha SCN4A 0.0041
153 Dopamine beta-hydroxylase DBH 0.0041
2449 Tubulin alpha-3 chain TUBA1A 0.0041
6432 Transporter snf 0.0041
84 Nuclear receptor 0B1 NR0B1 0.0041
6043 Putative G-protein coupled receptor 44 GPR44 0.0041
3997 Cytochrome P450 24A1, mitochondrial CYP24A1 0.0041
33 Cystine/glutamate transporter SLC7A11 0.0041
856 Vitamin D3 receptor VDR 0.004
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.004
3970 Voltage-dependent N-type calcium channel subunit alpha-1B CACNA1B 0.004
6032 PROBABLE FATTY ACID SYNTHASE FAS (FATTY ACID SYNTHETASE) fas 0.004
1618 High affinity nerve growth factor receptor NTRK1 0.004
365 Dihydrofolate reductase DHFR 0.004
2381 Dihydrofolate reductase DFR1 0.004
2833 Dihydrofolate reductase Not Available 0.004
2931 Dihydrofolate reductase folA 0.004
3544 Dihydrofolate reductase folA 0.004
3682 Dihydrofolate reductase folA 0.004
6642 Dihydrofolate reductase folA 0.004
6756 Dihydrofolate reductase dfrA 0.004
6150 Solute carrier organic anion transporter family member 4C1 SLCO4C1 0.0039
2268 Cholesterol oxidase choB 0.0039
2822 Cholesterol oxidase choA 0.0039
54 Prothrombin F2 0.0039
360 Ribonucleoside-diphosphate reductase large subunit RRM1 0.0039
823 Fibroblast growth factor receptor 2 FGFR2 0.0039
1129 C-C chemokine receptor type 5 CCR5 0.0039
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.0038
592 Carbonic anhydrase 4 CA4 0.0038
605 Fumarate reductase flavoprotein subunit frdA 0.0038
2709 Fumarate reductase flavoprotein subunit SO_0970 0.0038
3673 Fumarate reductase flavoprotein subunit fccA 0.0038
4912 Fumarate reductase flavoprotein subunit ifcA 0.0038
6549 Fumarate reductase flavoprotein subunit frdA 0.0038
1974 Oligopeptide transporter, kidney isoform SLC15A2 0.0038
215 Sodium channel protein type 11 subunit alpha SCN11A 0.0037
102 DNA topoisomerase I, mitochondrial TOP1MT 0.0037
6046 Voltage-gated calcium channel beta 1 subunit splice variant CavB1d CACNB1 0.0037
1525 Heparin-binding growth factor 2 FGF2 0.0037
891 Dihydropteroate synthase folP 0.0037
5359 Dihydropteroate synthase folP 0.0037
7175 Dihydropteroate synthase sulI 0.0037
2283 Steroid Delta-isomerase ksi 0.0037
2920 Steroid Delta-isomerase ksi 0.0037
3854 Basic fibroblast growth factor receptor 1 FGFR1 0.0037
1192 Sulfotransferase 1A1 SULT1A1 0.0036
918 Glutamate receptor, ionotropic kainate 2 GRIK2 0.0036
2808 Chloramphenicol acetyltransferase 3 cat3 0.0036
319 Opioid receptor, sigma 1 OPRS1 0.0036
780 Retinoic acid receptor RXR-gamma RXRG 0.0036
68 Cannabinoid receptor 1 CNR1 0.0036
904 Glutathione S-transferase P GSTP1 0.0036
543 Penicillin-binding protein 1B mrcB 0.0035
6186 Penicillin-binding protein 1B ponB 0.0035
6822 Penicillin-binding protein 1b pbp1b 0.0035
6844 Penicillin-binding protein 1b pbp1b 0.0035
3856 Fibroblast growth factor receptor 3 FGFR3 0.0035
5300 Antigen peptide transporter 1 TAP1 0.0035
185 Vasopressin V1a receptor AVPR1A 0.0035
778 Cysteinyl leukotriene receptor 1 CYSLTR1 0.0035
117 Sterol O-acyltransferase 1 SOAT1 0.0035
1787 Nuclear factor NF-kappa-B p105 subunit NFKB1 0.0035
159 Penicillin-binding protein 2B penA 0.0035
6121 Penicillin-binding protein 2B penA 0.0035
939 50S ribosomal protein L3 rplC 0.0035
1630 Integrin beta-2 ITGB2 0.0035
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0034
322 Vasopressin V2 receptor AVPR2 0.0034
2325 Sulfotransferase family cytosolic 2B member 1 SULT2B1 0.0034
2499 Tubulin beta-2C chain TUBB2C 0.0034
1457 Long-chain-fatty-acid--CoA ligase 4 ACSL4 0.0034
921 Glutamate receptor 2 GRIA2 0.0033
3601 Dihydropteroate synthase 1 folP1 0.0033
3807 Dihydropteroate synthase 1 folP1 0.0033
3808 Dihydropteroate synthase 2 folP2 0.0033
2417 Chloramphenicol acetyltransferase cat 0.0033
3278 Chloramphenicol acetyltransferase cat 0.0033
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.0033
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.0033
40 RAF proto-oncogene serine/threonine-protein kinase RAF1 0.0033
88 Retinoic acid receptor RXR-beta RXRB 0.0033
2810 Dr hemagglutinin structural subunit draA 0.0032
2718 Chloramphenicol 3-O phosphotransferase Not Available 0.0032
1759 85 kDa calcium-independent phospholipase A2 PLA2G6 0.0032
1770 Phospholipase C PLCL1 0.0032
2841 Phospholipase C plc 0.0032
140 30S ribosomal protein S9 rpsI 0.0031
6719 30S ribosomal protein S9 rpsI 0.0031
6725 30S ribosomal protein S9 rpsI 0.0031
276 Sodium- and chloride-dependent GABA transporter 1 SLC6A1 0.0031
280 4-aminobutyrate aminotransferase, mitochondrial ABAT 0.0031
4192 DNA topoisomerase 2-beta TOP2B 0.0031
1636 Trace amine-associated receptor 1 TAAR1 0.0031
3913 Glutamic acid decarboxylase GAD65 0.0031
482 Glycine receptor subunit alpha-1 GLRA1 0.0031
217 Estradiol 17-beta-dehydrogenase 1 HSD17B1 0.0031
1864 RET proto-oncogene RET 0.0031
200 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 0.0031
451 Carnitine O-palmitoyltransferase I, liver isoform CPT1A 0.0031
1950 Epithelial discoidin domain-containing receptor 1 DDR1 0.003
6094 BCR/ABL fusion protein isoform X9 BCR/ABL fusion 0.003
6170 ATP-binding cassette sub-family A member 3 ABCA3 0.003
2578 Tubulin beta-3 chain TUBB3 0.003
1353 DNA topoisomerase 1 TOP1 0.003
3552 DNA topoisomerase 1 topA 0.003
2285 Streptogramin A acetyltransferase vatD 0.003
741 Potassium voltage-gated channel subfamily KQT member 1 KCNQ1 0.003
6048 Troponin C, skeletal muscle TNNC2 0.0029
357 Carbonic anhydrase 2 CA2 0.0029
650 Aldo-keto reductase family 1 member C3 AKR1C3 0.0029
564 Cellular retinoic acid-binding protein 1 CRABP1 0.0029
3957 Adenosine deaminase ADA 0.0029
512 DNA-directed RNA polymerase alpha chain rpoA 0.0029
5772 DNA-directed RNA polymerase alpha chain rpoA 0.0029
992 Protein tyrosine kinase 2 beta PTK2B 0.0028
518 Peroxidase/catalase T katG 0.0028
5934 Cytochrome P450 26A1 CYP26A1 0.0028
6153 Solute carrier organic anion transporter family member 4A1 SLCO4A1 0.0028
859 Cellular retinoic acid-binding protein 2 CRABP2 0.0027
4173 Tyrosine-protein kinase JAK2 JAK2 0.0027
3849 Insulin-like growth factor-binding protein 7 IGFBP7 0.0027
2009 Protein NOV homolog NOV 0.0027
3847 Neuroendocrine convertase 2 PCSK2 0.0027
1949 Carboxypeptidase E CPE 0.0027
3850 Synaptotagmin-like protein 4 SYTL4 0.0027
3848 Neuroendocrine convertase 1 PCSK1 0.0027
3846 Retinoblastoma-associated protein RB1 0.0027
563 Thyroid peroxidase TPO 0.0026
3904 Alanine aminotransferase 2 GPT2 0.0026
735 Alanine aminotransferase 1 GPT 0.0026
790 DNA polymerase subunit alpha B POLA2 0.0026
3868 Calcineurin subunit B isoform 2 PPP3R2 0.0026
421 Calcium signal-modulating cyclophilin ligand CAMLG 0.0026
1648 Elastin ELN 0.0026
6179 UDP-glucuronosyltransferase 2B17 UGT2B17 0.0026
572 Integrin alpha-L ITGAL 0.0026
49 Endothelin B receptor EDNRB 0.0026
5880 Thrombopoietin receptor MPL 0.0025
241 Calcium-transporting ATPase type 2C member 1 ATP2C1 0.0025
390 Adenosine A3 receptor ADORA3 0.0025
634 Squalene monooxygenase SQLE 0.0025
7196 Squalene monooxygenase ERG1 0.0025
937 Proto-oncogene tyrosine-protein kinase LCK LCK 0.0024
578 Endothelin-1 receptor EDNRA 0.0024
544 Potassium voltage-gated channel subfamily E member 1 KCNE1 0.0024
6039 Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A PDE11A 0.0024
537 ATP synthase delta chain, mitochondrial ATP5D 0.0024
6070 Nischarin NISCH 0.0024
233 Potassium channel subfamily K member 2 KCNK2 0.0024
719 Retinoic acid receptor responder protein 1 RARRES1 0.0024
5852 Type-2 angiotensin II receptor AGTR2 0.0024
770 Retinoic acid-induced protein 3 GPRC5A 0.0024
6040 6-phosphogluconate dehydrogenase, decarboxylating PGD 0.0023
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0023
162 Retinoic acid receptor gamma-1 RARG 0.0023
550 Amiloride-sensitive sodium channel subunit delta SCNN1D 0.0023
27 Amiloride-sensitive sodium channel subunit beta SCNN1B 0.0023
552 Amiloride-sensitive sodium channel subunit gamma SCNN1G 0.0023
213 Amiloride-sensitive sodium channel subunit alpha SCNN1A 0.0023
1830 5'-nucleotidase NT5E 0.0023
837 Glutamate [NMDA] receptor subunit epsilon-1 GRIN2A 0.0023
522 26S proteasome non-ATPase regulatory subunit 2 PSMD2 0.0023
515 26S proteasome non-ATPase regulatory subunit 1 PSMD1 0.0023
559 NADH-ubiquinone oxidoreductase chain 1 MT-ND1 0.0023
6174 50S ribosomal protein L32 rpmF 0.0022
990 Dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 0.0022
5787 Angiopoietin-1 receptor TEK 0.0022
6146 High affinity copper uptake protein 1 SLC31A1 0.0022
581 Cytochrome P450 2R1 CYP2R1 0.0022
7 Nitric oxide synthase, inducible NOS2 0.0022
3404 Exotoxin A eta 0.0022
6824 Tyrosine-protein kinase Lyn LYN 0.0022
2155 Insulin-degrading enzyme IDE 0.0022
298 Renin REN 0.0021
935 Proto-oncogene tyrosine-protein kinase Yes YES1 0.0021
1063 Signal transducer and activator of transcription 5B STAT5B 0.0021
1638 Solute carrier family 2, facilitated glucose transporter member 2 SLC2A2 0.0021
2091 Endoplasmin HSP90B1 0.0021
1244 Low-density lipoprotein receptor-related protein 2 LRP2 0.0021
569 Retinal dehydrogenase 2 ALDH1A2 0.0021
6080 Neuronal acetylcholine receptor subunit alpha-5 CHRNA5 0.0021
6082 Neuronal acetylcholine receptor subunit beta-3 CHRNB3 0.0021
948 Neuronal acetylcholine receptor subunit beta-2 CHRNB2 0.0021
267 Plasminogen activator inhibitor 1 SERPINE1 0.0021
63 Malate dehydrogenase mdh 0.0021
2329 Malate dehydrogenase mdh 0.0021
3445 Malate dehydrogenase mdh 0.0021
4420 Malate dehydrogenase mdh 0.0021
4438 Malate dehydrogenase mdh 0.0021
751 Potassium channel subfamily K member 6 KCNK6 0.0021
164 Histamine H4 receptor HRH4 0.002
936 Ephrin type-A receptor 2 EPHA2 0.002
6126 Carbonic anhydrase 7 CA7 0.002
1524 Peptidyl-prolyl cis-trans isomerase A PPIA 0.002
6700 Peptidyl-prolyl cis-trans isomerase A ppiA 0.002
1820 Beta-nerve growth factor NGF 0.002
2216 Fibroblast growth factor receptor 4 FGFR4 0.002
611 Retinal dehydrogenase 1 ALDH1A1 0.0019
633 Penicillin-binding proteins 1A/1B pbpA 0.0019
183 Vascular endothelial growth factor A VEGFA 0.0019
908 Glutathione S-transferase theta-1 GSTT1 0.0019
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0019
5766 NAD-dependent deacetylase sirtuin-5 SIRT5 0.0019
6081 Neuronal acetylcholine receptor subunit alpha-6 CHRNA6 0.0019
4097 Neuronal acetylcholine receptor subunit alpha-9 CHRNA9 0.0019
6085 Fatty acid-binding protein, intestinal FABP2 0.0019
172 Potassium channel subfamily K member 1 KCNK1 0.0019
473 L-lactate dehydrogenase A chain LDHA 0.0019
934 Proto-oncogene tyrosine-protein kinase Fyn FYN 0.0019
368 Enoyl-[acyl-carrier-protein] reductase [NADH] inhA 0.0019
3228 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0019
3678 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0019
6856 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0019
3809 Estrogen-related receptor gamma ESRRG 0.0018
6221 Steroid hormone receptor ERR1 ESRRA 0.0018
893 [Citrate [pro-3S]-lyase] ligase citC 0.0018
845 Pyruvate dehydrogenase [cytochrome] poxB 0.0018
6140 Ileal sodium/bile acid cotransporter SLC10A2 0.0018
6766 O-GlcNAcase BT_4395 BT_4395 0.0018
1968 ATP-sensitive inward rectifier potassium channel 12 KCNJ12 0.0018
327 Glutathione reductase gor 0.0018
5110 Glutathione reductase GR2 0.0018
4103 Proteasome subunit beta type 2 PSMB2 0.0018
4102 Proteasome subunit beta type 5 PSMB5 0.0018
4101 Proteasome subunit beta type 1 PSMB1 0.0018
1374 Natriuretic peptides B NPPB 0.0018
1827 Gap junction alpha-1 protein GJA1 0.0018
1908 Vascular cell adhesion protein 1 VCAM1 0.0018
683 Potassium transporter GK0582 0.0018
748 5'-AMP-activated protein kinase catalytic subunit alpha-1 PRKAA1 0.0018
734 D1 dopamine receptor-interacting protein calcyon CALY 0.0018
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.0018
459 Retinoic acid receptor RXR-alpha RXRA 0.0018
67 Prolyl 4-hydroxylase subunit alpha-1 P4HA1 0.0017
484 Tyrosine-protein kinase ABL2 ABL2 0.0017
621 Periplasmic [Fe] hydrogenase 1 Not Available 0.0017
2450 Tyrosine-protein kinase ITK/TSK ITK 0.0017
2290 ADP-ribosyl cyclase 2 BST1 0.0017
439 Glutamate [NMDA] receptor subunit epsilon-4 GRIN2D 0.0017
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0017
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0017
2038 Inhibitor of nuclear factor kappa-B kinase subunit beta IKBKB 0.0017
78 Acetyl-CoA acetyltransferase, mitochondrial ACAT1 0.0016
144 Hemoglobin subunit alpha HBA1 0.0016
4209 ATP-sensitive inward rectifier potassium channel 8 KCNJ8 0.0016
1243 Cathepsin D CTSD 0.0016
3810 Catechol O-methyltransferase COMT 0.0016
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0016
6100 BDNF/NT-3 growth factors receptor NTRK2 0.0015
3233 Bile acid receptor NR1H4 0.0015
401 Glutamate [NMDA] receptor subunit zeta-1 GRIN1 0.0015
1502 Peroxisome proliferator-activated receptor delta PPARD 0.0015
3126 Poly [ADP-ribose] polymerase 1 PARP1 0.0015
6138 Multidrug resistance protein 3 ABCB4 0.0015
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0015
982 Cocaine- and amphetamine-regulated transcript protein CARTPT 0.0015
268 Adenosine A2b receptor ADORA2B 0.0015
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0015
3937 Fatty-acid amide hydrolase FAAH 0.0015
806 Sodium/potassium-transporting ATPase alpha-1 chain ATP1A1 0.0015
1714 Mitogen-activated protein kinase 3 MAPK3 0.0015
828 Phenylalanine-4-hydroxylase PAH 0.0015
3109 Phenylalanine-4-hydroxylase phhA 0.0015
3844 HLA class II histocompatibility antigen, DQ(6) alpha chain HLA-DQA2 0.0015
1939 Heat shock protein HSP 90-alpha HSP90AA1 0.0015
1541 Metalloproteinase mmp20 0.0014
3802 Sodium channel protein type 2 subunit alpha SCN2A 0.0014
1039 Histone deacetylase 9 HDAC9 0.0014
6167 Organic solute transporter subunit beta OSTB 0.0014
6166 Organic solute transporter subunit alpha OSTA 0.0014
1341 Histamine H3 receptor HRH3 0.0014
1262 Corticotropin-lipotropin POMC 0.0014
6859 Protein S100-A4 S100A4 0.0014
2184 Cystic fibrosis transmembrane conductance regulator CFTR 0.0013
244 Angiotensin-converting enzyme ACE 0.0013
2236 Casein kinase II subunit alpha CSNK2A1 0.0013
2180 3-phosphoinositide-dependent protein kinase 1 PDPK1 0.0013
6211 Tubulin epsilon chain TUBE1 0.0013
6212 Tubulin gamma-1 chain TUBG1 0.0013
6210 Tubulin delta chain TUBD1 0.0013
6123 Carbonic anhydrase 5A, mitochondrial CA5A 0.0013
1275 Estrogen sulfotransferase SULT1E1 0.0013
860 Nicotinamide N-methyltransferase NNMT 0.0013
5626 Nucleoside diphosphate kinase B NME2 0.0013
1650 Heme carrier protein 1 SLC46A1 0.0013
699 Nicotinic acid receptor 1 GPR109A 0.0013
928 Nicotinic acid receptor 2 GPR109B 0.0013
583 Nicotinate-nucleotide pyrophosphorylase [carboxylating] QPRT 0.0013
2442 Nicotinate-nucleotide pyrophosphorylase [carboxylating] nadC 0.0013
2459 Nicotinate-nucleotide pyrophosphorylase [carboxylating] nadC 0.0013
424 Dihydroorotate dehydrogenase, mitochondrial DHODH 0.0013
6116 Gastric triacylglycerol lipase LIPF 0.0012
182 2-oxoglutarate dehydrogenase E1 component, mitochondrial OGDH 0.0012
630 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial ACADSB 0.0012
6933 Calcium-activated potassium channel subunit beta-4 KCNMB4 0.0012
6931 Calcium-activated potassium channel subunit beta-1 KCNMB1 0.0012
6932 Calcium-activated potassium channel subunit beta-3 KCNMB3 0.0012
6934 Small conductance calcium-activated potassium channel protein 1 KCNN1 0.0012
6935 Small conductance calcium-activated potassium channel protein 2 KCNN2 0.0012
6936 Small conductance calcium-activated potassium channel protein 3 KCNN3 0.0012
760 Fibroblast growth factor 1 FGF1 0.0012
3806 cGMP-dependent 3',5'-cyclic phosphodiesterase PDE2A 0.0012
2157 NAD(P)H dehydrogenase [quinone] 1 NQO1 0.0012
3823 Cytokine receptor common gamma chain IL2RG 0.0012
85 Growth hormone receptor GHR 0.0012
2107 Microtubule-associated protein 1A MAP1A 0.0012
338 DNA polymerase UL30 0.0012
379 DNA polymerase UL54 0.0012
697 DNA polymerase ORF28 0.0012
2482 DNA polymerase 43 0.0012
4104 DNA polymerase BALF5 0.0012
896 Glutathione S-transferase Mu 1 GSTM1 0.0012
1295 Fatty acid synthase FASN 0.0012
5878 Alpha-7 nicotinic cholinergic receptor subunit CHRFAM7A 0.0012
505 Glutamate [NMDA] receptor subunit epsilon-3 GRIN2C 0.0011
1360 Sphingomyelin phosphodiesterase SMPD1 0.0011
1992 Vitamin D-binding protein GC 0.0011
754 Pancreatic triacylglycerol lipase PNLIP 0.0011
24 Thymidylate synthase TMP1 0.0011
359 Thymidylate synthase TYMS 0.0011
2626 Thymidylate synthase thyA 0.0011
2729 Thymidylate synthase thyA 0.0011
5352 Thymidylate synthase THYA 0.0011
707 72 kDa type IV collagenase MMP2 0.0011
5463 Calcium-activated potassium channel subunit beta 2 KCNMB2 0.0011
170 Succinate semialdehyde dehydrogenase, mitochondrial ALDH5A1 0.0011
838 Inosine-5'-monophosphate dehydrogenase 1 IMPDH1 0.0011
2178 Metabotropic glutamate receptor 5 GRM5 0.0011
796 Inosine-5'-monophosphate dehydrogenase 2 IMPDH2 0.0011
724 Interleukin-2 receptor alpha chain IL2RA 0.0011
717 Interleukin-2 receptor subunit beta IL2RB 0.0011
2300 Lysozyme E 0.001
3633 Lysozyme R 0.001
5597 Lysozyme 17 0.001
591 Glutamate [NMDA] receptor subunit 3B GRIN3B 0.001
251 Alcohol dehydrogenase 1A ADH1A 0.001
1810 Protein S100-A1 S100A1 0.001
6097 Protein S100-A2 S100A2 0.001
4116 Dihydropteroate synthetase Not Available 0.001
1144 Hepatocyte growth factor receptor MET 0.001
66 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II HSD3B2 0.001
493 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial CYP27B1 0.001
5294 Nucleoside diphosphate kinase A NME1 0.001
695 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A PDE10A 0.001
245 Large neutral amino acids transporter small subunit 1 SLC7A5 0.001
4041 Microsomal glutathione S-transferase 2 MGST2 0.001
291 Nitric-oxide synthase, endothelial NOS3 0.001
820 Glycine receptor subunit alpha-2 GLRA2 0.001
444 Alcohol dehydrogenase 1B ADH1B 0.0009
229 Retinoic acid receptor beta RARB 0.0009
1064 DNA (cytosine-5)-methyltransferase 1 DNMT1 0.0009
65 Matrix metalloproteinase-9 Not Available 0.0009
730 Retinoic acid receptor alpha RARA 0.0009
3917 Methylenetetrahydrofolate reductase MTHFR 0.0009
1048 Protein S100-A13 S100A13 0.0009
2226 Protein S100-A12 S100A12 0.0009
6149 Solute carrier family 22 member 10 SLC22A10 0.0009
6131 Carbonic anhydrase 14 CA14 0.0009
6160 Solute carrier organic anion transporter family member 3A1 SLCO3A1 0.0009
2132 Protein S100-B S100B 0.0009
382 Glutamate receptor, ionotropic kainate 1 GRIK1 0.0008
22 30S ribosomal protein S4 rpsD 0.0008
6714 30S ribosomal protein S4 rpsD 0.0008
6122 Carbonic anhydrase 3 CA3 0.0008
3830 Calreticulin CALR 0.0008
1867 Major prion protein PRNP 0.0008
517 Alcohol dehydrogenase 1C ADH1C 0.0008
2232 Interleukin-5 IL5 0.0008
1593 Mucin-2 MUC2 0.0008
4031 Glutathione S-transferase A1 GSTA1 0.0008
6034 Hydroxyindole O-methyltransferase ASMT 0.0008
500 Monocarboxylate transporter 4 SLC16A3 0.0008
6035 Nuclear receptor ROR-beta RORB 0.0008
6036 Eosinophil peroxidase EPX 0.0008
1649 Small inducible cytokine A2 CCL2 0.0008
1025 Aquaporin-1 AQP1 0.0008
400 Coagulation factor IX F9 0.0008
5461 Coagulation factor IX F9 0.0008
6893 Calcium/calmodulin-dependent protein kinase type II gamma chain CAMK2G 0.0007
6155 ATP-binding cassette transporter sub-family C member 11 ABCC11 0.0007
866 Large neutral amino acids transporter small subunit 2 SLC7A8 0.0007
4226 Uridine phosphorylase 2 UPP2 0.0007
461 Glycine receptor subunit alpha-3 GLRA3 0.0007
130 Prostacyclin synthase PTGIS 0.0007
6103 Arylamine N-acetyltransferase 1 NAT1 0.0007
822 Aldose reductase AKR1B1 0.0007
1768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit GNG2 0.0007
1268 Neuropeptide S receptor NPSR1 0.0007
1571 G protein-activated inward rectifier potassium channel 1 KCNJ3 0.0007
1581 G protein-activated inward rectifier potassium channel 2 KCNJ6 0.0007
4081 Vitamin K epoxide reductase complex subunit 1-like protein 1 VKORC1L1 0.0007
604 Vitamin K-dependent protein Z PROZ 0.0007
6228 Nuclear receptor coactivator 1 NCOA1 0.0007
6207 30S ribosomal protein S14 rpsN 0.0007
6209 30S ribosomal protein S19 rpsS 0.0007
6712 30S ribosomal protein S19 rpsS 0.0007
6726 30S ribosomal protein S19 rpsS 0.0007
6241 Nuclear receptor coactivator 2 NCOA2 0.0007
645 Penicillin-binding protein 1A mrcA 0.0007
5805 Penicillin-binding protein 1A ponA 0.0007
6185 Penicillin-binding protein 1A mrcA 0.0007
6799 Penicillin-binding protein 1A pbpA 0.0007
3876 Aromatic-L-amino-acid decarboxylase DDC 0.0007
2298 Cytochrome P450-cam camC 0.0007
226 Gonadotropin-releasing hormone receptor GNRHR 0.0007
765 Indoleamine 2,3-dioxygenase IDO1 0.0007
6172 ATP-binding cassette sub-family B member 8, mitochondrial ABCB8 0.0007
4225 Uridine phosphorylase 1 UPP1 0.0007
125 DNA polymerase beta POLB 0.0007
1123 Eosinophil cationic protein RNASE3 0.0007
2599 Tyrosine-protein kinase HCK HCK 0.0007
6073 Potassium channel subfamily K member 9 KCNK9 0.0006
6072 Potassium channel subfamily K member 3 KCNK3 0.0006
389 Amiloride-sensitive cation channel 2, neuronal ACCN2 0.0006
137 FolC bifunctional protein [Includes: Folylpolyglutamate synthase folC 0.0006
1245 Vitamin K-dependent protein S PROS1 0.0006
413 Amidophosphoribosyltransferase PPAT 0.0006
2515 Amidophosphoribosyltransferase purF 0.0006
3714 Amidophosphoribosyltransferase purF 0.0006
422 Vitamin K-dependent protein C PROC 0.0006
106 Cannabinoid receptor 2 CNR2 0.0006
4162 Potassium voltage-gated channel subfamily KQT member 3 KCNQ3 0.0006
364 Corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 0.0006
3426 Glutamine synthetase glnA 0.0006
3987 Glutamine synthetase GLUL 0.0006
890 Niemann-Pick C1-like protein 1 NPC1L1 0.0006
337 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial NDUFS7 0.0006
214 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial NDUFS3 0.0006
803 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial NDUFS2 0.0006
6168 Solute carrier family 22 member 16 SLC22A16 0.0006
3611 Cytidine deaminase cdd 0.0006
3707 Cytidine deaminase cdd 0.0006
4211 Cytidine deaminase CDA 0.0006
1291 cAMP response element-binding protein CREB1 0.0006
6163 Copper-transporting ATPase 2 ATP7B 0.0006
6165 Copper-transporting ATPase 1 ATP7A 0.0006
448 Vitamin K-dependent gamma-carboxylase GGCX 0.0006
6861 Alcohol dehydrogenase [NADP+] AKR1A1 0.0006
1569 G1/S-specific cyclin-D1 CCND1 0.0006
4210 Toll-like receptor 4 TLR4 0.0005
1760 Aminopeptidase N ANPEP 0.0005
6843 Aminopeptidase N pepN 0.0005
4152 Superoxide dismutase [Cu-Zn] SOD1 0.0005
3639 Thymidine phosphorylase deoA 0.0005
3936 Thymidine phosphorylase TYMP 0.0005
798 Osteocalcin BGLAP 0.0005
6151 Monocarboxylate transporter 10 SLC16A10 0.0005
2207 Rhodopsin RHO 0.0005
1302 Dihydropyrimidine dehydrogenase [NADP+] DPYD 0.0005
2981 Phospholipase A2, membrane associated PLA2G2A 0.0005
6002 Prostaglandin E2 receptor EP4 subtype PTGER4 0.0005
369 Coagulation factor VII F7 0.0005
3610 Thioredoxin reductase 1, cytoplasmic TXNRD1 0.0004
476 RAC-alpha serine/threonine-protein kinase AKT1 0.0004
4131 Prostaglandin E2 receptor, EP3 subtype PTGER3 0.0004
406 Prostaglandin E2 receptor, EP2 subtype PTGER2 0.0004
76 Nitric-oxide synthase, brain NOS1 0.0004
4217 Telomerase reverse transcriptase TERT 0.0004
1176 Mitogen-activated protein kinase 1 MAPK1 0.0004
594 Thyroxine-binding globulin SERPINA7 0.0004
758 Thyroid hormone receptor alpha THRA 0.0003
2240 Cell division protein kinase 2 CDK2 0.0003
3961 G protein-activated inward rectifier potassium channel 4 KCNJ5 0.0003
5798 Mitogen-activated protein kinase 11 MAPK11 0.0003
199 Monocarboxylate transporter 8 SLC16A2 0.0003
2320 Thymidine kinase, cytosolic TK1 0.0003
346 Thyroid hormone receptor beta-1 THRB 0.0003
6218 Pannexin-1 PANX1 0.0003
521 ATP-binding cassette transporter sub-family C member 9 ABCC9 0.0003
132 ATP-binding cassette sub-family A member 1 ABCA1 0.0002
6135 Sodium channel subunit beta-4 SCN4B 0.0002
6134 Sodium channel subunit beta-3 SCN3B 0.0002
6132 Sodium channel subunit beta-1 SCN1B 0.0002
6127 Carbonic anhydrase-related protein CA8 0.0002
6128 Carbonic anhydrase-related protein 10 CA10 0.0002
6133 Sodium channel subunit beta-2 SCN2B 0.0002
6129 Carbonic anhydrase-related protein 11 CA11 0.0002
709 ATP-sensitive inward rectifier potassium channel 1 KCNJ1 0.0002
3803 Sodium channel protein type 3 subunit alpha SCN3A 0.0002
6130 Carbonic anhydrase 13 CA13 0.0002
6124 Carbonic anhydrase 5B, mitochondrial CA5B 0.0002
489 Monocarboxylate transporter 2 SLC16A7 0.0002
3007 Carbonic anhydrase 12 CA12 0.0002
4205 Carbonic anhydrase 9 CA9 0.0002
4936 Cytochrome c2 iso-2 Not Available 0.0001
4916 Cyanoglobin glbN 0.0001
4994 Hemoglobin-like protein HbO glbO 0.0001
4915 Cytochrome c-550 psbV 0.0001
4959 Cytochrome c-550 psbV 0.0001
5216 Cytochrome c-550 psbV 0.0001
4925 Cytochrome c-type protein SHP shp 0.0001
4904 Cytochrome c family protein GSU1996 0.0001
4943 Cytochrome c6 petJ 0.0001
3116 Bacterioferritin bfr 0.0001
4906 Bacterioferritin bfr 0.0001
4965 Bacterioferritin bfr 0.0001
4954 Soluble cytochrome b558 Not Available 0.0001
4934 Cytochrome c-551 nirM 0.0001
5218 Cytochrome c-551 nirM 0.0001
4905 Cytochrome c2 Not Available 0.0001
4939 Cytochrome c2 cycA 0.0001
4964 Cytochrome c2 cycA 0.0001
4979 Cytochrome c2 cycA 0.0001
6673 Cytochrome c2 cycA 0.0001
4910 Cytoglobin CYGB 0.0001
4984 Neuroglobin NGB 0.0001
4981 Iron-starvation protein PigA pigA 0.0001
4909 CooA protein cooA 0.0001
4998 Hemoglobin-like protein yjbI yjbI 0.0001
4935 Cytochrome c-554 cycA1 0.0001
4947 Bacterial hemoglobin vhb 0.0001
4975 Cytochrome c-556 RPA3973 0.0001
4942 Diheme cytochrome c napB napB 0.0001
4931 Cytochrome P450 167A1 CYP167A1 0.0001
5000 HemO hemO 0.0001
4972 P450cin cinA 0.0001
4960 Putative cytochrome P450-family protein SCO7417 0.0001
4971 Nonaheme cytochrome c hmcA 0.0001
4989 Cytochrome c551 peroxidase ccp 0.0001
5222 Cytochrome c551 peroxidase ccpA 0.0001
4961 Hemophore HasA hasA 0.0001
4976 Apocytochrome f petA 0.0001
6407 Apocytochrome f petA 0.0001
4907 Cytochrome c-L moxG 0.0001
6865 Cytochrome c-L moxG 0.0001
4993 Hydroxylamine oxidoreductase hao1 0.0001
4764 Cytochrome P450 165C4 CYP165C4 0.0001
4926 Heme-based aerotactic transducer hemAT hemAT 0.0001
644 Heme oxygenase 2 HMOX2 0.0001
4982 Heme oxygenase 2 pbsA2 0.0001
4952 Catalase/peroxidase katA 0.0001
4970 Cytochrome c nitrite reductase catalytic subunit nrfA 0.0001
4937 Cytochrome oxidase subunit II rcoxA 0.0001
4903 Methyl-accepting chemotaxis protein Tar4 0.0001
4999 Cytochrome P450 165B3 CYP165B3 0.0001
3093 Catalase HPII katE 0.0001
4908 Heme-regulated cyclic AMP phosphodiesterase dosP 0.0001
4922 Cytochrome c, putative SO_4144 0.0001
4920 Peroxidase/catalase katG 0.0001
4990 PpcA ppcA 0.0001
4948 Cytochrome c-553 Not Available 0.0001
4923 Cytochrome c3 DvMF_2499 0.0001
4945 Cytochrome c3 Not Available 0.0001
4949 Cytochrome c3 DVU_3171 0.0001
4968 Cytochrome c3 cytc3 0.0001
4997 Cytochrome c3 SO_2727 0.0001
5219 Cytochrome c3 cyd 0.0001
2119 Cytochrome b5 CYB5A 0.0001
4902 Nine-heme cytochrome c Ddes_2038 0.0001
3189 High-molecular-weight cytochrome c hmcA 0.0001
4956 Quinohemoprotein alcohol dehydrogenase ADH IIB qbdA 0.0001
3375 Acidic cytochrome c3 Not Available 0.0001
4988 Sulfite oxidase, mitochondrial SUOX 0.0001
2915 Sensor protein fixL fixL 0.0001
4944 Sensor protein fixL fixL 0.0001
4813 Heme oxygenase hmuO 0.0001
5769 Heme oxygenase Not Available 0.0001
3570 Cytochrome P450 152A1 cypC 0.0001
4385 Cytochrome c' Not Available 0.0001
4967 Cytochrome c' cycA 0.0001
5038 Cytochrome c' Not Available 0.0001
5223 Cytochrome c' cycP 0.0001
4037 Hypothetical protein GPX1 0.0001
4297 Hypothetical protein SP_1951 0.0001
4521 Hypothetical protein BC_2969 0.0001
4540 Hypothetical protein TM_1070 0.0001
4555 Hypothetical protein MT1739 0.0001
4569 Hypothetical protein mshD 0.0001
4578 Hypothetical protein PA3270 0.0001
4747 Hypothetical protein PA3967 0.0001
5177 Hypothetical protein TM_0096 0.0001
5194 Hypothetical protein PA1204 0.0001
5240 Hypothetical protein Rv2991 0.0001
5370 Hypothetical protein TM_1158 0.0001
5710 Hypothetical protein Tb927.5.1360 0.0001
4289 Cytochrome P450 TT_P0059 0.0001
6262 Cytochrome P450 staP 0.0001
4992 Cytochrome c peroxidase Not Available 0.0001
2230 Catalase CAT 0.0001
3249 Catalase katA 0.0001
3625 Catalase katA 0.0001
4539 Catalase katA 0.0001
4941 Catalase katB 0.0001
3670 Soluble cytochrome b562 precursor cybC 0.0001
3411 Cytochrome P450 121 cyp121 0.0001
3291 Cytochrome c-552 cycA 0.0001
4927 Cytochrome c-552 nrfA 0.0001
4938 Cytochrome c-552 cycA 0.0001
4953 Cytochrome c-552 nrfA 0.0001
5217 Cytochrome c-552 cycM 0.0001
2617 Nitric oxide synthase oxygenase nos 0.0001
2701 Nitric oxide synthase oxygenase nos 0.0001
3102 Flavohemoprotein hmp 0.0001
4969 Flavohemoprotein hmp 0.0001
4386 Hemoglobin-like protein HbN glbN 0.0001
3127 Nitrite reductase nirS 0.0001
3284 Nitrite reductase nirS 0.0001
2845 Bifunctional P-450:NADPH-P450 reductase CYP102A1 0.0001
2972 6-deoxyerythronolide B hydroxylase eryF 0.0001
3221 Cytochrome c4 cc4 0.0001
4608 Putative cytochrome P450 SCO1207 0.0001
4963 Putative cytochrome P450 SCO2884 0.0001
6254 Putative cytochrome P450 SCO6998 0.0001
358 Cystathionine beta-synthase CBS 0
1507 Cytochrome c CYCS 0
693 Hemoglobin subunit beta HBB 0
6268 Hydroxyacid oxidase 1 HAO1 0
810 Heme oxygenase 1 HMOX1 0
3391 Heme oxygenase 1 pbsA1 0
↑